Chinese medicine listed companies that have been in the “undervalued” team are finally proud!
Recently, the Chinese medicine sector continued to change. On December 27, Tianjin Chase Sun Pharmaceutical Co.Ltd(300026) , Lanzhou Foci Pharmaceutical Co.Ltd(002644) , Jinghua Pharmaceutical Group Co.Ltd(002349) , Dali Pharmaceutical Co.Ltd(603963) announced abnormal fluctuations in stock trading one after another. According to the data, on the same day, 23 A-share listed companies of traditional Chinese medicine increased by more than 5%, of which China Resources Sanjiu Medical & Pharmaceutical Co.Ltd(000999) , Kunming Longjin Pharmaceutical Co.Ltd(002750) , Jinghua Pharmaceutical Group Co.Ltd(002349) , Teyi Pharmaceutical Group Co.Ltd(002728) reported the daily limit.
Shi lichen, an expert in pharmaceutical strategic planning, told the Securities Daily that the recent rise in the share price of Listed Companies in the traditional Chinese medicine industry is affected by multiple factors, including the rise in the price of traditional Chinese medicine, the implementation of centralized collection of traditional Chinese medicine and the continuous promulgation of policies conducive to the development of traditional Chinese medicine in recent years. “However, it will take a long time from the implementation of the policy to the substantive change in the traditional Chinese medicine industry.”
The continuous rise in the price of traditional Chinese medicine this year has aroused widespread concern in the market. On December 21, Chongqing Taiji Industry (Group) Co.Ltd(600129) said on the investor interaction platform that due to the continuous rise in the costs of main raw materials, auxiliary materials and energy, in order to alleviate the pressure of rising costs, the company has recently adjusted the ex factory price of Huoxiang Zhengqi oral liquid, with an average increase of 12%.
Jiuzhitang Co.Ltd(000989) in response to investors’ questions, he said that recently, the price of traditional Chinese medicine raw materials has generally increased due to the influence of climate, planting area and other factors, especially the scarcity of precious and fine raw materials and the contradiction between supply and demand.
On December 24, Shanghai New World Co.Ltd(600628) said in response to investors’ questions that the price adjustment of the company’s traditional Chinese medicine decoction pieces has increased and decreased, and the retail price has been adjusted twice in the past year. Shanghai Cai Tongde Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, is a whole industry chain company with one-stop supply, production and marketing. Its subsidiary Wujiang Shanghai Cai Tongde Tang traditional Chinese medicine decoction pieces Co., Ltd. has a certain scale of original inventory of traditional Chinese medicine. This year, the retail price of traditional Chinese medicine decoction pieces increased, coupled with the increase in the sales volume of decoction pieces, and the gross profit increased to a certain extent in the first half of the year.
The research report released by Soochow Securities Co.Ltd(601555) believes that the price of upstream raw materials in the OTC market of Chinese patent medicine increases, and relevant enterprises have the willingness and ability to raise prices, which is expected to usher in a simultaneous rise in volume and price.
When the prices of some traditional Chinese medicine products rise, the volume procurement of Chinese patent medicine has also attracted much market attention. On December 21, Hubei pharmaceutical price and bidding procurement management service network released the proposed winning results of centralized volume procurement of inter provincial alliance of Chinese patent medicines. The provincial alliance centralized procurement of Chinese patent medicine started in September this year, led by Hubei Province. It is the largest centralized procurement operation in the field of Chinese patent medicine so far. According to media reports, a total of 193 enterprises in the centralized purchase of Chinese patent medicines passed the examination and participated in the election. 111 products of 97 enterprises were selected, with a winning rate of 62%. The average price of centralized purchase decreased by 42.27% and the maximum decline was 82.63%.
Shi lichen told reporters that in the future, the centralized purchase of Chinese patent medicine will have a far-reaching impact on the industry. On the one hand, it can increase the market share of some enterprises, on the other hand, it will reduce the product price. Referring to the centralized purchase of chemical generic pharmaceutical industry, Chinese patent medicine enterprises also need to accelerate the pace of transformation. “Either to the field of innovative drugs such as biological drugs, or increase the development of traditional Chinese medicine products to prevent the development dilemma of single products.”
According to the research report released by Soochow Securities Co.Ltd(601555) , the state has made great efforts to support the traditional Chinese medicine industry. In 2021, the number of CDE traditional Chinese medicine acceptance numbers increased from more than 400 in 2020 to more than 1200 in 2021; Since 2021, the approval of innovative Chinese traditional medicine has accelerated. As of December 24, 11 innovative Chinese patent medicines have been approved.
“Centralized mining will become a watershed in the development of the traditional Chinese medicine industry. Enterprises without innovation investment will gradually shrink their market value in the future.” Shi lichen thinks.
(Securities Daily)
